|Publication number||US3676557 A|
|Publication date||Jul 11, 1972|
|Filing date||Mar 2, 1971|
|Priority date||Mar 2, 1971|
|Publication number||US 3676557 A, US 3676557A, US-A-3676557, US3676557 A, US3676557A|
|Inventors||Lachman Leon, Reiner Roy H, Shami Elie, Spector Walter|
|Original Assignee||Endo Lab|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (7), Non-Patent Citations (4), Referenced by (86), Classifications (5), Legal Events (1)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent Lachman et al.
[ 51 July 11,1972
 LONG-ACTING NARCOTIC ANTAGONIST FORMULATIONS Hempstead; Walter Specter, Valley Stream, all of NY.
 Assignee: Endo Laboratories, Inc., Garden City,
 Filed: March 2, 1971  Appl.No.: 120,336
Related U.S. Application Data  Continuation-impart of Ser. No. 56,975, July 21,
[$2] U.S. Cl. ..424/260 [5 1] Int. Cl. ..A6lk 27/12  Field of Search ..424/244, 260
 References Cited UNITED STATES PATENTS 3,254,088 5/1966 Lowenstein ..260/285 3,332,950 7/ l 967 3,326,896 6/1967 2,964,448 12/1960 2,507,193 5/ 1950 Buckwalter ..424/271 FOREIGN PATIEN'I'S OR APPLICATIONS 1,461,407 12/1966 France 6,706,464 6/1968 South Africa OTHER PUBLICATIONS Thompson, Am. J. Trop. Med. Hyg. 12, 481 (1963) McGregor, Brit. Med. .1. 695, Mar. 19, 1966 Coatney, Am. J. Trop. Med. Hyg. 12, 504 1963) Waltz, Science, 141 723, Aug. 1963 Blumberg et al ..260/285 Primary ExaminerShep K. Rose AuomeyDon M. Kerr  ABSTRACT The pamoate salts of N-(cyclopropylmethyl)-7,8-dihydro-14- hydroxynormorphinone and N-allyl-7,8-dihydro-l4-hydroxynormorphinone, in oil suspension, are injectable, long-acting forms of these narcotic antagonists.
3 Claims, No Drawings LONG-ACTING NARCOTIC ANTAGONIST FORMULATIONS RELATED APPLICATIONS This application is a continuation-in-part of application Ser. No. 56,975, filed July 21, 1970 now abandoned.
BACKGROUND OF THE INVENTION This invention relates to the known narcotic antagonists, N- allyl-7,8-dihydro-l4-hydroxynormorphinone and N- (cyclopropylmethyl)-7,8-dihydro-l4-hydroxynormorphinone. The former compound will sometimes be referred to hereinafter by its generic name, naloxone.
Naloxone and certain of its salts are disclosed in US. Pat. No. 3,254,088 as potent narcotic antagonists. A report by Fink et al., Naloxone in Heroin Dependence," Clinical Pharmacology and Therapeutics, Vol. 9, No. 5, pp. 568-577 (1968) confirms that naloxone is a highly potent antagonist which is relatively free of adverse side, effects. Fink et al. note however that the antagonist action of naloxone is quite brief, and conclude:
The short duration of action may be a serious limitation. Further trials of the narcotic antagonist treatment model are necessary, and naloxone is the best drug available for such studies, but pharmaceutical ingenuity may create compounds with longer durations of action and equal potency and safety.
N-(cyclopropylmethyl)-7,8-dihydro-l4-hydroxynormorphinone and certain of its salts are disclosed in U.S. Pat. No. 3,332,950. This compound is also a potent narcotic antagonist but, like naloxone it suffers the disadvantage of relatively short duration of action.
SUMMARY OF THE INVENTlON DESCRIPTION OF THE INVENTION Di-naloxone pamoate is an odorless, light yellowish-tan powder with the empirical formula (C,,,H ,NO,,) -C H ,O,
and the structural fonnula:
. C OOH CH -CH=CH: I l OH HO I H2 OH H!) 2 COOH Di-naloxone pamoate is prepared by mixing naloxone hydrochloride with disodium pamoate in a 2:1 molar ratio in aqueous solution. The relatively insoluble di-naloxone pamoate precipitates, is removed by filtration, purified by recrystallization from ethanol or other suitable solvent, and dried. The product need not be anhydrous. it will ordinarily contain at least 1 mole of water and may contain up to about 10 percent by weight of combined or uncombined water and/or combined or uncombined solvent. A specific procedure which can be used to produce di-naloxone pamoate is as follows:
To a solution of 9.6 g. (0.024 mol) of naloxone hydrochloride monohydrate in approximately l00.ml. water a solution of 5.4 g. (0.012 mol) of disodium pamoate monohydrate in a similar volume of water is slowly added, with stirring. The precipitate, which forms almost instantaneously, is stirred for about 1 hour, the solvent is filtered off, and the residue washed with water and then dried. Yield: 12 g'.
Recrystallization from 300 ml. of boiling ethanol yields 8 g. of product, which, after drying for 3 hours at in a vacuum oven, decomposes at l98225 C.
Di-[N-(cyclopropylmethyl)-7,8-dihydro-14-hydroxynormorphinone] pamoate is an odorless, buff-colored powder with the empirical formula (C ,,H ',NO,,) -C.,, -,H ,0 and the structural formula: I
: coon r l N OH OH: HO I Hi) 0 2 COOH Di-[N-(cyclopropylmethyl)-7,S-dihydro-14-hydroxynormorphinone] pamoate is prepared in a manner similar to that used for preparing di-naloxone pamoate, and like di-naloxone pamoate it may contain up to about 10 percent by weight of combined or uncombined water and/or solvent. A specific procedure which can be used to produce this salt is as follows:
To a solution of 5.7 g. (0.015 mol) of N-(cyclopropylmethyl )-7,8-dihydro- 1 4hydroxynormorphinone hydrochloride in approximately 100 ml. water a solution of 3.4 g. (0.0075 mol) of disodium pamoate monohydrate in a similar volume of water is slowly added, with stirring. The precipitate which fonns is stirred for about an hour, filtered, and the residue washed with water and dried. Yield: 7.2 g.
Recrystallization from ethanol yields 6.1 g. in two crops, which are combined and dried for 3 hours at 100 C. in a vacuum oven to give material which decomposes at 200-207 C.
The oil medium for suspensions of this invention can be any vegetable oil which is suitable for parenteral use. The vegetable oil, for example, may be peanut oil, corn oil, sesame oil, or cottonseed oil.
ln order to provide stable suspensions, a viscosity-increasing agent is incorporated into the vegetable oil. Suitable viscosityincreasing agents are the fatty acid salts of aluminum, especially those containing about seven to 25 carbon atoms. Aluminum monostearate is particularly preferred. The aluminum monostearate or other viscosity-increasing agent will ordinarily be used in an amount in the range of from 01-50 percent (w/v), based on the oil. The preferred range is 1.0-4.0 percent (w/v).
The viscosity-increasing agent is incorporated into the vegetable oil with agitation and heating as necessary to produce a stable vegetable oil gel. For example, an aluminum monostearate gel can be prepared by suspending an amount of aluminum monostearate in a suitable vegetable oil. Under constant agitation, heat is applied until a temperature of 85-90 C. is attained. A heating rate of 5 C. per minute is applied until this temperature is reached. This temperature is maintained for 30-45 minutes to eliminate water from the system. Heating is continued, but retarded to 23 C. per minute until a temperature of C. is attained. 15 minutes stirring at this temperature will stabilize the gel that is formed. Using this technique, vegetable oil gels can be made at temperatures between 125C. and C.
A preservative can be added to the vegetable oil gel, if desired, in an amount ordinarily used in injectable dosage forms, i.e. about 0.05 percent to 0.5 percent (w/v) based on oil. The parabens, in combinations ordinarily used in parenterals, are preferred, but other preservatives recognized for use in parenterals (e.g. phenol, cresol, chlorobutanol) can also be used.
Antioxidants commonly used in pharmaceutical products may also be incorporated. These include, for example, ascorbyl palmitate, hydroquinone, propyl gallate, nordihydroguaiaretic acid, butylated hydroxy toluene, butylated hydroxy anisole, a-tocopherol and its esters, phenyl anaphthylamine, lecithin, and mixtures of these. The amount of antioxidant, when used, will ordinarily be in the range from about 0.005 to 0.2 percent (w/v) based on the oil.
The suspensions of the invention can also contain other therapeutically active compounds, in amounts sufficient to enhance the utility of the formulation for its intended purpose. These adjuvants can be formulated so as to be released immediately or over an extended period of time. Examples of other types of therapeutically active ingredients which can be included in the suspensions, either as the compounds themselves or their pharmaceutically acceptable salts, are:
a. major tranquilizers, such as chlorpromazine or molindone, or minor tranquilizers, such as chlordiazepoxide, glutethimide or pentobarbital, for the symptomatic relief of narcotic withdrawal symptoms;
b. analeptics, such as picrotoxin or pentamethylenetetrazole, or central nervous system stimulants such as methylphenidate, for antagonism of acute respiratory depression caused by agents other than narcotics; and
0. various narcotics or other narcotic antagonists such as methadone, meperidine or cyclazocine, in dosage ratios which provide retention of analgesia or appropriate withdrawal therapy, while simultaneously minimizing side effects.
ln preparing the suspensions of the invention the di-naloxone pamoate or di-[N-(cyclopropylmethyl)-7,8-dihydro-l4- hydroxynormorphinone] pamoate is added to the vegetable oil gel in amounts equivalent to naloxone hydrochloride or N- cycloproylmethyl-7,8-dihydro-l4-hydroxynormorphinone hydrochloride (anhydrous basis) in the range from about 1 to about 500 mg./ml. of suspension, preferably 2 to 200 mg./ml., more preferably to 100 mg./ml. The mixture is then mechanically worked to reduce the particle size of the suspended materials and thoroughly disperse them in the gel. The average particle size of the suspended materials should be sufficiently small that the suspension is syringeable through a 20 gauge needle. It is preferred that the average particle size be between 5 and 50 microns, and that essentially all of the particles be less than about 100 microns. Particle size reduction and dispersion of the suspended materials can be accomplished with the use of a laboratory blender, colloid mill, sonic mill, or other comparable equipment.
Aseptic techniques may be used throughout the preparation, or other suitable techniques for making sterile parenterals can be used.
A suspension of the invention, containing an amount of dinaloxone pamoate equivalent to mg. of naloxone hydrochloride per ml. in 2 percent aluminum monostearate in peanut oil, was tested for duration of Numorphan-antagonist effect in mice. The test used was the subcutaneous counteraction of the Numorphan HCl induced Straub tail in mice. Two tests, each using three mice, were made. Each mouse received one injection of the above formulation (5 cc./kg.) and was challenged with a Numorphan HCl injection (2 mg./kg.) at various time intervals thereafter. Results, expressed as the number of mice protected out of three, were as follows:
Time ofChallengc Test 1 Test 2 minutes 3/3 3/3 24 minutes 3/3 3/3 48 hours 2/3 2/3 72 hours 0/3 The fact that all of the mice were protected at 15 minutes shows that the suspension of the invention provides quick onset of action. At the same time the suspension provided protection to all of the mice for 24 hours and for two thirds of the mice for 48 hours. In contrast, an aqueous solution of naloxone hydrochloride protects mice for only about 5 hours.
The same formulation was also tested for duration of effect in rats. The test was subcutaneous injection for prevention of Numorphan induced loss of righting reflex. Two tests, each using four rats, were made. Each rat received one subcutaneous injection of the above formulation (1 cc./kg.) and was challenged with a subcutaneous Numorphan injection (l mg./kg.) at various time intervals thereafter. The rats were considered protected if they did not lose their righting reflex in 30 minutes after the Numorphan subcutaneous challenge. Results, expressed as the number of rats protected out of four. were as follows:
Time of Challenge Test l Test 2 15 minutes 4/4 4/4 24 hours 3/4 3/4 48 hours 2/4 3/4 72 hours l/4 25 Another suspension of the invention, containing an amount of di-naloxone pamoate equivalent to 50 mg. of naloxone hydrochloride per ml. in 2 percent aluminum monostearate in peanut oil, was tested for duration of effect in dogs. Six dogs were used. Each dog received one I.M. injection of the di- 3 naloxone pamoate suspension. The dosage was 0.1 cc./kg. for two dogs and 0.2 cc./kg. for the other four. Numorphan HCl was given at various time intervals thereafter; the dosage was 0.5 mg./kg. l.V., a prostrating dose. The following is the score system used:
0 Prostration, head drop no protection I Head weakness slight protection 2 Hind and front leg weakness moderate protection 3 Hind leg weakness only almost complete protection 4 Normal, no effect complete protection.
Results were as follows:
Antagonist Time Intervals Dog Dosage 24 48 72 96 7 l0 l4 2| NoJSex (co/kg.) hrs. hrs. hrs. hrs. days days days days l/M 0.l 4 3 0 (i/M 0.2 3 l O In a similar test on two dogs, using a suspension of the invention containing an amount of di-naloxone pamoate equivalent to 50 mg. of naloxone hydrochloride per ml. of 2 percent aluminum monostearate in sesame oil, results showed that a dosage of 0.2 cc./kg. gives almost complete protection against Numorphan after 17 days.
A suspension of the invention, containing an amount of di- [N-(cyclopropylmethyl)-7,8-dihydrol 4-hydroxynormorphinone] pamoate equivalent to 10 mg. of N-cyclopropylmethyl- 7,8-dihydro-l4-hydroxynormorphinone hydrochloride per ml., in a peanut oil gel containing 2 percent aluminum monostearate, was compared with an aqueous control solution containing 10 mg./ml. of the N-(cyclopropylmethyl)-7,8- dihydro-l4-hydroxynormorphinone hydrochloride for duration of Numorphan antagonist effect in mice. The same formulations, as well as the di-naloxone pamoate formulation described above in the rat test, were also compared for duration of Numorphan antagonist effect in rats.
In the mouse: The protocol was the same as that described above for the test of the di-naloxone pamoate suspension in mice, except that each individual animal was challenged only once with a subcutaneous injection of Numorphan (different groups of mice being challenged at the various time intervals), and groups of animals were used for each point. Results, expressed as the number of mice protected out of 10, are shown in the following table; column D shows the results for mice injected with the suspension of the invention, and column C shows the results for the mice injected with the control solution.
Time of Challenge C D minutes 10/ 10 10/10 2 hours 10/10 6 hours 6/10 24 hours 0/10 9/10 48 hours 2/10 72 hours 0/10 In the rat: The protocol was the same as that described above for the test of the di-naloxone pamoate suspension in rats, except that each individual animal was challenged only once with a subcutaneous injection of Numorphan (different groups of rats being challenged at the various time intervals), the dosage of the test or control solution was 10 mg./kg., and groups of 10 animals were used for each point, except that a group of only five animals was used for the 92 hour period. Results, expressed as the number of rats protected out of 10 (or five) are shown in the following table; column D shows the results for rats injected with the di-[N-(cyclopropylmethyl)- 7,8-dihydrol 4-hydroxynormorphinone] pamoate suspension, column C shows the results for rats injected with the control solution and column E shows the results for rats injected with the di-naloxone pamoate suspension.
Time of Challenge C D E 30 minutes 10/10 10/10 l0/l0 1 hour 10/10 6 hours 8/10 24hours0/l0 10/10 10/10 41hours- 9/10 4/10 48 hours 6/10 2/10 65 hours 1/10 0/l0 72 hours- 1/10 0/10 92 hours 0/5 What is claimed is:
1. An injectable, long-acting narcotic antagonist formulation, syringeable through a 20 gauge needle, which comprises:
A. particles of a salt selected from the group consisting of di-(N-allyl-7,8-dihydro-14-hydroxynormorphinone) pamoate and di-[N-(cyclopropyl-methyl)-7,8-dihydro-14 -hydroxynormorphinone] pamoate, the average particle size of the salt being between 5 and 50 microns, and essentially all of the particles being less than microns, thoroughly dispersed and suspended in B. a gel composed of a vegetable oil which is suitable for subcutaneous or intramuscular administration, gelled with about 0.1 to 5 percent w/v of aluminum monostearate, the concentration of the pamoate salt in the gel being equivalent to a concentration of the corresponding hydrochloride salt in the range of about 1 to about 500 mg./ml.
2. Formulation of claim 1 wherein the vegetable oil is selected from the group consisting of peanut oil, corn oil, sesame oil, and cottonseed oil.
3. Formulation of claim 2 wherein the concentration of the pamoate salt in the gel is equivalent to a concentration of the corresponding hydrochloride salt in the range of about 2 to 200 mg./ml., and the concentration of aluminum monostearate in the vegetable oil is in the range of about 1.0 to 4.0 percent w/v.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2507193 *||May 17, 1949||May 9, 1950||Bristol Lab Inc||Penicillin product|
|US2964448 *||Jan 27, 1959||Dec 13, 1960||Anschel Joachim||Relaxin composition and process for preparing same|
|US3254088 *||Mar 14, 1961||May 31, 1966||Lewenstein||Morphine derivative|
|US3326896 *||Jul 8, 1965||Jun 20, 1967||Geigy Chem Corp||Embonic acid addition salts of 10, 11-dihydro-5h-dibenz[b, f]azepines|
|US3332950 *||Dec 6, 1966||Jul 25, 1967||Endo Lab||14-hydroxydihydronormorphinone derivatives|
|FR1461407A *||Title not available|
|ZA6706464A *||Title not available|
|1||*||Coatney, Am. J. Trop. Med. Hyg. 12, 504 (1963)|
|2||*||McGregor, Brit. Med. J. 695, Mar. 19, 1966|
|3||*||Thompson, Am. J. Trop. Med. Hyg. 12, 481 (1963)|
|4||*||Waltz, Science, 141, 723, Aug. 1963|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4218454 *||May 24, 1978||Aug 19, 1980||Sri International||N-αMethylcyclopropylmethyl derivatives of normorphine and noroodeine, and analgesic compositions and methods employing the normorphine derivatives|
|US4269843 *||Jul 8, 1980||May 26, 1981||Sri International||N-Sec-alkyl analogs of norcodeine and normorphine and analgesic compositions and methods employing the normorphine derivatives|
|US4457933 *||Dec 11, 1981||Jul 3, 1984||Bristol-Myers Company||Prevention of analgesic abuse|
|US6228863||Dec 22, 1998||May 8, 2001||Euro-Celtique S.A.||Method of preventing abuse of opioid dosage forms|
|US6254884||Jun 11, 1998||Jul 3, 2001||Lg Chemical Ltd.||Somatotropin compositions mixed with vitamins|
|US6277384||Dec 22, 1998||Aug 21, 2001||Euro-Celtique S.A.||Opioid agonist/antagonist combinations|
|US6375957||Feb 11, 2000||Apr 23, 2002||Euro-Celtique, S.A.||Opioid agonist/opioid antagonist/acetaminophen combinations|
|US6475494||Mar 22, 2001||Nov 5, 2002||Euro-Celtique S.A.||Opioid agonist/antagonist combinations|
|US6617321||May 1, 2002||Sep 9, 2003||Eli Lilly And Company||2-methyl-thieno-benzodiazepine formulation|
|US6627635||Mar 22, 2001||Sep 30, 2003||Euro-Celtique S.A.||Method of preventing abuse of opioid dosage forms|
|US6656508||Apr 17, 1997||Dec 2, 2003||Amgen Inc.||Sustained-release alginate gels|
|US6696066||Sep 16, 2002||Feb 24, 2004||Euro-Celtique S.A.||Opioid agonist/antagonist combinations|
|US6696088||Feb 8, 2001||Feb 24, 2004||Euro-Celtique, S.A.||Tamper-resistant oral opioid agonist formulations|
|US6716449||Feb 8, 2001||Apr 6, 2004||Euro-Celtique S.A.||Controlled-release compositions containing opioid agonist and antagonist|
|US7172767||Oct 27, 2003||Feb 6, 2007||Purdue Pharma L.P.||Opioid agonist / antagonist combinations|
|US7303764||Jul 3, 2003||Dec 4, 2007||Eli Lilly And Company||2-methyl-thieno-benzodiazepine formulation|
|US7384653||Sep 23, 2004||Jun 10, 2008||Purdue Pharma L.P.||Oral dosage form comprising a therapeutic agent and an adverse-effect agent|
|US7419686||Dec 26, 2006||Sep 2, 2008||Purdue Pharma L.P.||Opioid agonist/antagonist combinations|
|US7658939||Nov 4, 2003||Feb 9, 2010||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US7682632||Mar 23, 2010||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US7682633||Mar 6, 2009||Mar 23, 2010||Alpharma Pharmaceuticals, Llc||Pharmaceutical composition|
|US7682634||Mar 23, 2010||Alpharma Pharmaceuticals, Llc||Pharmaceutical compositions|
|US7718192||Nov 4, 2003||May 18, 2010||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US7749542||Jul 6, 2010||Purdue Pharma Lp||Opioid agonist/antagonist combinations|
|US7842309||Nov 30, 2010||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US7842311||Nov 30, 2010||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US7914818||Aug 6, 2002||Mar 29, 2011||Purdue Pharma L.P.||Opioid agonist formulations with releasable and sequestered antagonist|
|US7932249||Dec 22, 2005||Apr 26, 2011||Eli Lilly And Company||Olanzapine pamoate dihydrate|
|US7943173||Jul 18, 2002||May 17, 2011||Purdue Pharma L.P.||Pharmaceutical combinations of oxycodone and naloxone|
|US8105631||Jan 31, 2012||Purdue Pharma L.P.||Opioid agonist/antagonist combinations|
|US8158156||Jun 19, 2007||Apr 17, 2012||Alpharma Pharmaceuticals, Llc||Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist|
|US8182836||Jun 5, 2009||May 22, 2012||Elite Laboratories, Inc.||Abuse-resistant oral dosage forms and method of use thereof|
|US8231901||Jul 31, 2012||Purdue Pharma L.P.||Opioid agonist formulations with releasable and sequestered antagonist|
|US8236351||Oct 21, 2010||Aug 7, 2012||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US8357399||Jan 22, 2013||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US8425933||Apr 23, 2013||Elite Laboratories, Inc.||Abuse-resistant oral dosage forms and method of use thereof|
|US8465774||Feb 13, 2006||Jun 18, 2013||Purdue Pharma L.P.||Sequestered antagonist formulations|
|US8518443||Jun 28, 2012||Aug 27, 2013||Purdue Pharma, L.P.||Opioid agonist formulations with releasable and sequestered antagonist|
|US8586088||Dec 18, 2012||Nov 19, 2013||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US8623418||Dec 16, 2008||Jan 7, 2014||Alpharma Pharmaceuticals Llc||Pharmaceutical composition|
|US8673355||Dec 27, 2011||Mar 18, 2014||Purdue Pharma L.P.||Opioid agonist/antagonist combinations|
|US8685443||Apr 23, 2010||Apr 1, 2014||Alpharma Pharmaceuticals Llc||Sequestering subunit and related compositions and methods|
|US8685444||Apr 23, 2010||Apr 1, 2014||Alpharma Pharmaceuticals Llc||Sequestering subunit and related compositions and methods|
|US8703186||Apr 16, 2013||Apr 22, 2014||Elite Laboratories, Inc.||Abuse-resistant oral dosage forms and method of use thereof|
|US8758825||May 22, 2013||Jun 24, 2014||Purdue Pharma L.P.||Sequestered antagonist formulations|
|US8815287||Jul 29, 2013||Aug 26, 2014||Purdue Pharma L.P.||Opiod agonist formulations with releasable and sequestered antagonist|
|US8822487||Dec 7, 2012||Sep 2, 2014||Purdue Pharma L.P.||Opioid agonist/opioid antagonist/acetaminophen combinations|
|US8846090||Jan 11, 2012||Sep 30, 2014||Euro-Celtique S.A.||Matrix for sustained, invariant and independent release of active compounds|
|US8846091||Oct 18, 2013||Sep 30, 2014||Euro-Celtique S.A.||Matrix for sustained, invariant and independent release of active compounds|
|US8846104||Feb 13, 2012||Sep 30, 2014||Alpharma Pharmaceuticals Llc||Pharmaceutical compositions for the deterrence and/or prevention of abuse|
|US8877247||Feb 22, 2010||Nov 4, 2014||Alpharma Pharmaceuticals Llc||Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist|
|US8932630||Sep 18, 2014||Jan 13, 2015||Purdue Pharma L.P||Opioid agonist/antagonist combinations|
|US8936808||Sep 18, 2014||Jan 20, 2015||Purdue Pharma L.P.||Opioid agonist/opioid antagonist/acetaminophen combinations|
|US8936812||Oct 4, 2013||Jan 20, 2015||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US8969369||Dec 20, 2013||Mar 3, 2015||Purdue Pharma L.P.||Abuse-resistant controlled-release opioid dosage form|
|US9056051||Mar 11, 2014||Jun 16, 2015||Purdue Pharma L.P.||Abuse-resistant controlled-release opioid dosage form|
|US9084729||Oct 30, 2013||Jul 21, 2015||Purdue Pharma L.P.||Abuse-resistant controlled-release opioid dosage form|
|US9149436||Apr 19, 2004||Oct 6, 2015||Purdue Pharma L.P.||Pharmaceutical product comprising a sequestered agent|
|US9161937||May 29, 2015||Oct 20, 2015||Purdue Pharma L.P.||Abuse-resistant controlled-release opioid dosage form|
|US9168252||May 29, 2015||Oct 27, 2015||Purdue Pharma L.P.||Abuse-resistant controlled-release opioid dosage form|
|US9205082||Mar 14, 2014||Dec 8, 2015||Purdue Pharma L.P.||Opioid agonist/antagonist combinations|
|US9271940||Mar 10, 2010||Mar 1, 2016||Purdue Pharma L.P.||Immediate release pharmaceutical compositions comprising oxycodone and naloxone|
|US9278073||Mar 23, 2015||Mar 8, 2016||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US9283216||Sep 18, 2015||Mar 15, 2016||Purdue Pharma L.P.||Abuse-resistant controlled-release opioid dosage form|
|US9283221||Sep 18, 2015||Mar 15, 2016||Purdue Pharma L.P.||Abuse-resistant controlled-release opioid dosage form|
|US9345701||Feb 3, 2016||May 24, 2016||Purdue Pharma L.P.||Abuse-resistant controlled-release opioid dosage form|
|US9358230||Feb 3, 2016||Jun 7, 2016||Purdue Pharma L.P.||Abuse-resistant controlled-release opioid dosage form|
|US20030073714 *||Aug 6, 2002||Apr 17, 2003||Christopher Breder||Opioid agonist formulations with releasable and sequestered antagonist|
|US20030157168 *||Aug 6, 2002||Aug 21, 2003||Christopher Breder||Sequestered antagonist formulations|
|US20040086561 *||Oct 27, 2003||May 6, 2004||Kaiko Robert F.||Opioid agonist / antagonist combinations|
|US20040092542 *||Nov 4, 2003||May 13, 2004||Benjamin Oshlack||Tamper-resistant oral opioid agonist formulations|
|US20040097489 *||Jul 3, 2003||May 20, 2004||Allen Douglas J.||2-methyl-thieno-benzodiazepine formulation|
|US20040186121 *||Oct 21, 2003||Sep 23, 2004||Benjamin Oshlack||Tamper-resistant oral opioid agonist formulations|
|US20040228924 *||Apr 19, 2004||Nov 18, 2004||Benjamin Oshlack||Pharmaceutical products|
|US20050095291 *||Nov 4, 2003||May 5, 2005||Benjamin Oshlack||Tamper-resistant oral opioid agonist formulations|
|US20050192309 *||Sep 18, 2003||Sep 1, 2005||Palermo Philip J.||Method of preventing abuse of opioid dosage forms|
|US20070122348 *||Dec 26, 2006||May 31, 2007||Purdue Pharma L.P.||Opioid agonist/antagonist combinations|
|US20080096871 *||Dec 22, 2005||Apr 24, 2008||Bush Julie K||Olanzapine Pamoate Dihydrate|
|US20080167533 *||Feb 28, 2006||Jul 10, 2008||Petra Leyendecker||Method and Device for the Assessment of Bowel Function|
|US20080292694 *||Jul 28, 2008||Nov 27, 2008||Purdue Pharma L.P.||Opioid agonist/antagonist combinations|
|US20080306104 *||Nov 4, 2003||Dec 11, 2008||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US20080311199 *||Nov 4, 2003||Dec 18, 2008||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|US20100291203 *||Nov 18, 2010||Purdue Pharma L.P.||Opioid Agonist/Antagonist Combinations|
|US20110097404 *||Oct 21, 2010||Apr 28, 2011||Purdue Pharma L.P.||Tamper-resistant oral opioid agonist formulations|
|USRE45822||Oct 28, 2013||Dec 22, 2015||Purdue Pharma L.P.||Oral dosage form comprising a therapeutic agent and an adverse-effect agent|
|EP0137600A1 *||Jul 19, 1984||Apr 17, 1985||Euroceltique S.A.||Pharmaceutically active salts of morphine|
|U.S. Classification||514/282, 546/45|
|Nov 22, 1982||AS||Assignment|
Owner name: E.I. DU PONT DE NEMOURS AND COMPANY, 1007 MARKET S
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ENDO LABORATORIES, INC., A CORP. OF DEL.;REEL/FRAME:004063/0107
Effective date: 19821110